Naveris aims for NavDx to improve treatment selection in patients with HPV-based head and neck cancers. NavDx analyzes tumor-derived DNA from patients’ blood samples to monitor for residual molecular disease, according to an April 12 Naveris news release.
“This clinical trial represents a significant step forward in personalized medicine for head and neck cancer patients,” Piyush Gupta, PhD, founder and CEO of Naveris, said in the release. “NavDx has the potential to be a game-changer in treatment selection, allowing physicians to tailor treatment plans to individual patients based on their unique biomarker profiles.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
